Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 11Genitourinary 5Endocrine 4Other 3Classical hematology 3Thoracic 2NET 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Neuroendocrine Tumors 378Carcinoid Tumor 40Gastro-enteropancreatic neuroendocrine tumor 36Pancreatic Neoplasms 27Carcinoma, Neuroendocrine 27Neoplasms 25Adenoma, Islet Cell 23Pheochromocytoma 17Paraganglioma 17Neoplasm Metastasis 17Stomach Neoplasms 15Neuroblastoma 14Gastrointestinal Neoplasms 14Carcinoma, Hepatocellular 12Thyroid Neoplasms 11Prostatic Neoplasms 11Breast Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Colorectal Neoplasms 10Lung Neoplasms 9Rectal Neoplasms 8Gastrointestinal Stromal Tumors 8Cholangiocarcinoma 8Carcinoma, Medullary 8Carcinoma 8Brain Neoplasms 8Anus Neoplasms 8Liver Neoplasms 7Colonic Neoplasms 7

Interventions

fluorodopa F 18 2Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Parkinson Disease × NET × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡